Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 1;39(2):223-230.
doi: 10.1097/HJH.0000000000002632.

Transgender adults, gender-affirming hormone therapy and blood pressure: a systematic review

Paul J Connelly  1 , Anna Clark, Rhian M Touyz, Christian Delles
Affiliations

Transgender adults, gender-affirming hormone therapy and blood pressure: a systematic review

Paul J Connelly et al. J Hypertens. .

Abstract

Objectives: Gender-affirming hormone therapy (GHT) is utilized by people who are transgender to align their secondary sex characteristics with their gender identity. Data relating to cardiovascular outcomes in this population are limited. We aimed to review the impact of GHT on the blood pressure (BP) of transgender individuals.

Methods: We searched PubMed/MEDLINE, SCOPUS and Cochrane Library databases for articles published relating to the BP of transgender adults commencing GHT. Methodological quality was assessed via the 'Quality Assessment Tool for Before-After (Pre-Post) Studies with No Control Group'.

Results: Six hundred articles were screened, of which 14 studies were included in this systematic review encompassing 1309 individuals (∼50% transgender men and women) treated with GHT between 1989 and 2019. These articles were all pre-post observational studies without control groups. Mean ages ranged between 23.0-36.7 years (transgender men) and 25.2-34.8 years (transgender women). Interventions were diverse and included oral, transdermal and injectable hormonal preparations with 4 months to 5 years follow-up. Most studies in transgender men did not demonstrate a change in BP, whereas transgender women on GHT demonstrated both increases and decreases in SBP. These studies were heterogenous with significant methodological limitations and only two were determined to have a good quality rating.

Conclusion: There is currently insufficient data to advise the impact of GHT on BP in transgender individuals. Better quality research is essential to elucidate whether exogenous sex hormones modulate BP in transgender people and whether this putative alteration infers poorer cardiovascular outcomes.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Flow diagram for study selection.
See this image and copyright information in PMC

References

    1. T'Sjoen G, Arcelus J, Gooren L, Klink DT, Tangpricha V. Endocrinology of transgender medicine. Endocr Rev 2019; 40:97–117. - PubMed
    1. Arcelus J, Bouman WP, Van Den Noortgate W, Claes L, Witcomb G, Fernandez-Aranda F. Systematic review and meta-analysis of prevalence studies in transsexualism. Eur Psychiatry 2015; 30:807–815. - PubMed
    1. Meerwijk EL, Sevelius JM. Transgender population size in the United States: a meta-regression of population-based probability samples. Am J Public Health 2017; 107:e1–e8. - PMC - PubMed
    1. Thomson RM, Katikireddi SV. Improving the health of trans people: the need for good data. Lancet Public Health 2019; 4:e369–e370. - PMC - PubMed
    1. Irwig MS. Cardiovascular health in transgender people. Rev Endocr Metab Disord 2018; 19:243–251. - PubMed

Publication types